The Thrombin Generation Test (TGT, also known as the thrombin generation assay or calibrated automated thrombography) is a global coagulation assay that continuously measures the kinetics and total quantity of thrombin produced in plasma, offering a far more complete picture of hemostatic balance than conventional PT and aPTT tests. It is widely applied to evaluate bleeding tendency, assess prothrombotic risk, and monitor the pharmacodynamic effects of anticoagulant and hemostatic therapies. This article explains the technical principle, sample requirements, measured parameters, testing methods, clinical applications, and frequently asked questions related to the thrombin generation test.
Technical Overview
The thrombin generation test (TGT), also called the thrombin generation assay (TGA) or calibrated automated thrombography (CAT), is a global hemostasis assay that monitors the rate and total amount of thrombin generated in a plasma sample after coagulation is triggered by tissue factor. Because thrombin is the central enzyme of the coagulation cascade, responsible for fibrin formation, platelet activation, and feedback amplification of factors V, VIII, and XI, the thrombin generation curve provides a functional summary of the procoagulant, anticoagulant, and regulatory influences acting simultaneously in the sample.
Conventional screening tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) terminate measurement at the first appearance of a fibrin clot and therefore capture only the initiation phase of coagulation. In contrast, the TGT follows the complete time course of thrombin activity over 60 to 120 minutes, covering the initiation, propagation, and termination phases, and yields quantitative parameters that correlate with both bleeding tendency and thrombotic risk. For this reason it is classified as a second-line, global coagulation assay used in specialized hemostasis laboratories and by accredited third-party laboratories supporting clinical trials and pharmaceutical studies.
The assay is performed on platelet-poor plasma (PPP) or platelet-rich plasma (PRP) using a fluorogenic or, less commonly, chromogenic substrate. Results are reported as a calibrated thrombin generation curve with parameters including lag time, time to peak, peak thrombin concentration, velocity index, and endogenous thrombin potential (ETP). Laboratories offering this test typically operate under quality management systems compliant with ISO 15189 or ISO/IEC 17025 to ensure traceable, reproducible results.
Testing Samples
Platelet-Poor Plasma (PPP)
PPP is the most widely used matrix for thrombin generation testing. Venous blood is collected into 3.2 percent (0.109 mol/L) trisodium citrate tubes at a strict 9:1 blood-to-anticoagulant ratio. The sample is double-centrifuged, typically at 2,000 to 2,500 times gravity for 10 to 15 minutes with a second centrifugation of the separated plasma, to reduce the residual platelet count to below 10 x 10^9/L. Because platelet surfaces are removed during preparation, exogenous phospholipids are supplied in the trigger reagent. PPP can be aliquoted and stored frozen at minus 70 degrees Celsius or below for extended periods, although repeated freeze-thaw cycles must be avoided.
Platelet-Rich Plasma (PRP)
PRP retains the patient's own platelets and therefore allows evaluation of the platelet contribution to thrombin generation, including the effects of platelet count, platelet activation state, and antiplatelet drugs. PRP is prepared by gentle centrifugation, for example at 150 to 200 times gravity for 10 minutes, and the platelet count is standardized, commonly to approximately 150 x 10^9/L, by dilution with autologous PPP. No exogenous phospholipid is added. PRP should be kept at room temperature with gentle mixing and tested within a few hours of collection because it cannot be frozen without destroying platelet function.
Other Matrices
For specialized research and transfusion medicine applications, thrombin generation can also be measured in whole blood, in platelet concentrates to assess transfusion potency, or in purified coagulation factor preparations for potency testing. These formats require dedicated method development and validation.
Pre-Analytical Considerations
Correct pre-analytical handling is the most important determinant of result quality. Blood should be drawn with minimal stasis and rapid venipuncture, grossly hemolyzed or clotted samples must be rejected, and fill volume deviations of more than 10 percent invalidate the citrate ratio. For anticoagulant monitoring, the intended time point (peak or trough) must be documented. Sample centrifugation, storage temperature, and transport time directly influence ETP and peak values.
Testing Items
A complete thrombin generation test reports the following quantitative parameters derived from the calibrated thrombin generation curve:
- Lag time (minutes): the interval between addition of the trigger reagent and the first measurable thrombin formation; reflects the initiation phase of coagulation.
- Time to peak, ttPeak (minutes): the time from triggering until the maximum thrombin concentration is reached.
- Peak thrombin concentration (nmol/L): the maximum thrombin activity achieved during the assay; reflects propagation capacity and clot-forming potential.
- Endogenous thrombin potential, ETP (nmol x min): the area under the thrombin generation curve, representing the total enzymatic work performed by thrombin; widely regarded as the most robust summary parameter.
- Velocity index (nmol/L per minute): the average rate of thrombin formation during the propagation phase, calculated as the slope between the lag time and the time to peak.
- Start tail (minutes): the time at which free thrombin activity declines toward baseline, reflecting the efficiency of anticoagulant pathways such as antithrombin and the protein C system.
Additional derived protocols include thrombin generation in the presence of thrombomodulin or activated protein C, which sensitizes the assay to acquired resistance to the protein C pathway and supports antiphospholipid syndrome evaluation.
Testing Methods
Fluorogenic Substrate Method (Calibrated Automated Thrombography)
The fluorogenic method is the current standard approach. Plasma is dispensed into microplate wells or dedicated cuvettes, and coagulation is initiated by a trigger reagent containing tissue factor (commonly 1 or 5 pmol/L), synthetic phospholipids (for PPP assays), and calcium chloride at a final concentration of approximately 16.7 mmol/L. A slow-cleaving fluorogenic thrombin substrate, typically Z-Gly-Gly-Arg-AMC, is present in the reaction mixture. Thrombin cleaves the substrate and releases aminomethylcoumarin, whose fluorescence is recorded with excitation around 390 nm and emission around 460 nm at 20 to 60 second intervals for up to 90 to 120 minutes using a microplate fluorometer or a dedicated thrombin generation analyzer.
Because substrate consumption, inner filter effects, and plasma-dependent quenching distort the raw fluorescence signal, each sample is measured in parallel with a calibrator containing a known, constant activity of thrombin complexed with alpha2-macroglobulin. The calibrator converts fluorescence velocity into absolute thrombin activity, producing a calibrated curve from which all parameters are computed by differentiation and correction algorithms.
Chromogenic and Subsampling Methods
Historically, thrombin generation was quantified by subsampling, in which aliquots of the clotting mixture were transferred at fixed intervals into buffer containing a chromogenic thrombin substrate and read photometrically. Although labor-intensive and largely replaced by continuous fluorogenic measurement, chromogenic and subsampling techniques remain useful in reference laboratories and methods requiring optical independence from plasma turbidity.
Quality Control and Calibration
Each analytical run should include a pooled normal plasma or commercial reference plasma as well as control plasmas covering normal and suppressed thrombin generation. Reagent lot-to-lot verification, instrument maintenance, and calibration verification are required elements of the quality system. Platelet counts in PRP and residual platelet contamination in PPP must be documented because they directly influence phospholipid-dependent results. Accredited third-party laboratories complying with ISO 15189 or ISO/IEC 17025 provide documented method validation, traceable calibrators, and auditable result reporting, which is particularly important for multi-center clinical studies.
Applications
Hemophilia and Rare Bleeding Disorders
ETP and peak thrombin correlate more closely with clinical bleeding phenotype in hemophilia A and B than one-stage factor assays. The test is used to individualize prophylaxis, to compare factor concentrates and extended-half-life products, and to monitor bypassing agents such as activated prothrombin complex concentrate and recombinant activated factor VII in patients with inhibitors. It also demonstrates the hemostatic efficacy of bispecific factor VIIIa-mimetic antibodies, which cannot be assessed by conventional aPTT.
Monitoring of Anticoagulant Therapy
Thrombin generation is suppressed in a dose-dependent manner by unfractionated heparin, low molecular weight heparins, vitamin K antagonists, and direct oral anticoagulants, including direct thrombin inhibitors such as dabigatran and direct factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban. The assay supports pharmacodynamic profiling at peak and trough time points, perioperative planning, assessment of reversal agents, and evaluation of special populations such as patients with renal impairment, pediatric patients, and pregnant women.
Assessment of Prothrombotic States
Elevated ETP and peak thrombin have been associated with increased venous thromboembolism risk, hormonal therapy, pregnancy complications, cancer-associated thrombosis, and the postoperative state. Modified protocols with thrombomodulin help detect activated protein C resistance and support the laboratory workup of antiphospholipid syndrome.
Liver Disease, Transfusion, and Perioperative Medicine
In cirrhosis, thrombin generation can remain near normal despite prolonged PT, supporting the concept of rebalanced hemostasis and guiding blood product use. In transfusion medicine, the assay evaluates the potency of plasma and platelet components. In cardiac surgery and extracorporeal membrane oxygenation, it helps characterize both bleeding risk and heparin effect beyond standard activated clotting time measurements.
Drug Development and Biomedical Research
The assay is a core tool for screening procoagulant and anticoagulant compounds, characterizing the potency of plasma-derived and recombinant factor concentrates, comparing biosimilar candidates, and quantifying procoagulant activity of novel hemostatic agents during preclinical and clinical development.
FAQ
How does the thrombin generation test differ from PT and aPTT?
PT and aPTT measure only the time until the first fibrin formation, whereas the TGT follows thrombin activity throughout initiation, propagation, and termination. This allows the TGT to detect both hypo- and hypercoagulable states, to integrate the effects of multiple factors and inhibitors, and to reflect the pharmacodynamics of modern anticoagulants and hemostatic drugs that conventional tests miss.
What sample is required and how should it be handled?
A citrated plasma sample is required: double-centrifuged platelet-poor plasma for standard testing or gently prepared platelet-rich plasma for platelet-inclusive assessment. PPP may be frozen at minus 70 degrees Celsius or below, while PRP should be tested within a few hours at room temperature without agitation-induced activation.
Is there a universal reference interval for the results?
No. ETP, peak, and lag time values depend on tissue factor concentration, phospholipid composition, substrate, and instrument platform. Each laboratory must establish its own reference intervals from a healthy donor population, and interpretation should always use the reference data of the performing laboratory.
Can the test be used to monitor direct oral anticoagulants?
Yes. The assay shows a clear dose-response relationship with both direct thrombin inhibitors and direct factor Xa inhibitors. It is particularly useful for integrated pharmacodynamic assessment, for example before urgent surgery or after overdose, although drug-specific calibration and defined decision thresholds are still being harmonized.
How long does the test take and what affects its accuracy?
The measurement itself typically runs 60 to 120 minutes, with same-day reporting in routine settings. The main sources of variability are pre-analytical, including incorrect citrate ratio, platelet contamination of PPP, hemolysis, storage conditions, and delayed testing, which is why standardized preparation and quality-controlled procedures are essential.
Is the method standardized?
International harmonization of reagents, calibrators, and reporting is an active area of work, and comparability between laboratories is improving. For clinical trials and multi-site studies, testing by accredited third-party laboratories with validated, ISO 15189 or ISO/IEC 17025 compliant methods ensures consistent and traceable results across study sites.
